Skip to main content
Skip to section navigation
Skip to footer
Maravai LifeSciences
Main Menu
Contact
Search
About
Show submenu
About Maravai
Leadership
Board of Directors
Innovation
Supply Chain
Operations
Diversity, Equity, and Inclusion
Brands
Show submenu
Our Brands
TriLink BioTechnologies
Cygnus Technologies
Glen Research
Alphazyme
Impact
Show submenu
Our Impact
Maravai Foundation
Insights
Show submenu
Our Insights
Maravai Insights
From the Science and Innovation Office
Latest news
Investors
Show submenu
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
ESG
Governance
Careers
Show submenu
Be a #MiracleMaker
Current Openings
Benefits and Growth
Culture and People
All SEC filings
Investors
Investors
Overview
News & Events
Press Releases
IR Calendar
Presentations
Email Alerts
R&D Day 2023
Company Info
Company Profile
Leadership
Annual Reports & Proxy
Contacts
FAQ
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
ESG
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Whistleblower Policy
Filing type:
View All
10-K
10-Q
144
3
4
4/A
424B4
5
8-A12B
8-K
ARS
CERT
CORRESP
DEF 14A
DRS
DRS/A
DRSLTR
EFFECT
PRE 14A
S-1
S-1/A
S-1MEF
S-8
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
Date
Form
Description
PDF
XBRL
Pages
04/06/21
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Documents
expand_more
EX-1.1
61
04/05/21
8-K
Current report filing
Documents
expand_more
EX-99.1
7
04/05/21
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
2
04/05/21
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
2
04/05/21
S-1
General form of registration statement for all companies including face-amount certificate companies
Documents
expand_more
EX-5.1
EX-23.1
87
04/01/21
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
1
03/25/21
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
80
03/22/21
10-K
Annual report pursuant to Section 13 and 15(d)
Documents
expand_more
EX-4.2
EX-21.1
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
163
03/02/21
8-K
Current report filing
Documents
expand_more
EX-99.1
12
02/16/21
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
4
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
…
Page
16
Page
17
Page
18
Page
19
Page
20
Page
21
Page
22
Page
23
Page
24
Page
25
…
Page
28
Next Page
arrow_forward
Select a page:
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Email Alerts
Company Profile
Contacts
RSS News Feed